Biora Therapeutics Inc (NAS:BIOR)
$ 0.678 0.02 (3.04%) Market Cap: 24.73 Mil Enterprise Value: 66.36 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 33/100

Progenity Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 22, 2021 / 02:40PM GMT
Release Date Price: $81.25
Andrew Cooper
Raymond James & Associates, Inc. - Analyst

Good morning, everyone. Thanks for joining us at the Raymond James Human Health Innovation Conference. I'm Andrew Cooper, and I cover diagnostics here for Raymond James.

And we are excited and happy to have Progenity joining us this morning. The Company is in the midst of a little bit of a transition here, exiting the genetic testing market -- or reproductive health market a little bit to focus on the pipeline that's really exciting, most immediately in -- with its preeclampsia rule-out test that I'm sure we'll talk about. And then really some interesting assets in drug delivery and sampling and testing in a pill-based platform, primarily targeting the GI and GI tract initially.

So I'm joined by CEO, Harry Stylli; and CFO, Eric d'Esparbes. (Conference Instructions) Maybe to start, I'm going to turn it over to Harry just to give us a little bit of flavor on where you were, where you are today, what's changed over the last few months that led to this decision to make a little bit of a transition, and what has you most excited

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot